SHARE

GlycoMimetics Inc (NASDAQ:GLYC), which happens to be one of the industry leaders has come forward to make an announcement regarding the decision by the U.S. Food and Drug Administration (FDA) to grant it a Breakthrough Therapy designation.

This was to ensure the treatment of adult relapsed/refractory acute myeloid leukemia (AML) to the provider’s drug candidate GMI-1271, an E-selectin antagonist that is at this particular point under close evaluation in the Phase 2 portion of a Phase 1/2 clinical trial in patients that have been compelled to put up with AML and its accompanying discomforts.

The ongoing clinical trial has had patients with relapsed or refractory AML and even those that are 60 years of age and above, that have newly been diagnosed with the complication administered with chemotherapy and GMI-1271.

As a matter of fact, the trial gave rise to data that was later on presented in the meetings of the American Society of Hematology (ASH) and the European Hematology Association (EHA) and it goes without saying that 2016 was a year that inspired great hope for all patients globally that have been were struggling with related complications.

To cut it to the chase, the passage of time is witnessing the sprouting of numerous health complications, some of which are being contained or countered in the best possible way. However, some of the health disorders are showing up as rather complex and that is the reason as to why a lot of funds are being redirected towards research by most of the research institutions as well as companies to help counter the menace.

 It is pretty clear that GlycoMimetics Inc is actually doing all it can to help struggling patients globally and that is clear from its efforts as well as then huge amount of resources it has been investing in research. We can only hope for the very best!

The Chief Medical Officer of GlycoMimetics, Helen Thackray while addressing a press conference said, “The FDA’s granting to GMI-1271 of Breakthrough Therapy designation will further help GlycoMimetics to accelerate the development of GMI-1271 as a treatment for this very difficult-to-treat patient population.”As a matter of fact it is a new dawn for patients suffering from the condition and the company remains committed to doing even much more.

LEAVE A REPLY